fluticasone / Generic mfg. - LARVOL DELTA

Cardiac disorders associated with compound long-acting bronchodilators for inhalation: a pharmacovigilance analysis of the FDA adverse event reporting system database. (PubMed, Front Cardiovasc Med) - "Compound ILABs had significant CAE risk signals, especially those of atrial fibrillation, myocardial infarction and heart failure, and the risk signal was stronger in the early stage of drug treatment. Except for a few individual adverse events, the overall CAE risk signal associated with triple inhaled agents (mainly Fluticasone/umeclidinium/vilanterol) was comparable to that of dual bronchodilators."

Adverse events • Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Myocardial Infarction

Alopecia Mucinosa Progressing to Folliculotropic Mycosis Fungoides in a Patient with Atopic Dermatitis (AAD 2026) - "Methotrexate, topical fluticasone, and UVA-1 phototherapy led to 80% reduction of lesions at two months and lesion clearance at four months... Deep follicular biopsies with IHC profiles are crucial when facial mucinous plaques persist despite conventional therapy. Early systemic and phototherapeutic intervention can yield excellent dermatologic and cosmetic outcomes for F-MF while simultaneously controlling co-existing AD."

Clinical • Alopecia • Atopic Dermatitis • Cutaneous T-cell Lymphoma • Dermatitis • Dermatology • Immunology • Mycosis Fungoides • Oncology • CD4

Glenmark Pharmaceuticals Limited has secured a significant regulatory milestone with the United States Food & Drug Administration (U.S. FDA) granting final approval for its Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). (Scanx)

ANDA • Allergy

CLINICAL CHARACTERISTICS AND TREATMENT RESPONSE OF NON-INFECTIOUS PULMONARY COMPLICATIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE ANALYSIS (EBMT 2026) - "Commonly used drugs included calcineurin inhibitors (tacrolimus/cyclosporine), corticosteroids, JAK inhibitors (e.g., ruxolitinib), and components of the "FAM" regimen (fluticasone, azithromycin, montelukast). NIPCs following HSCT are a significant complication affecting long-term quality of life. Their clinical presentation is often nonspecific and coexists with chronic GVHD in other organs. Exertional dyspnea is a core symptom, while obstructive patterns on PFTs and air trapping on CT are key diagnostic clues."

Retrospective data • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cough • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Pulmonary Disease • Respiratory Diseases • Transplantation

MANAGEMENT OF SEVERE PULMONARY COMPLICATIONS FOLLOWING HSCT IN A PATIENT WITH Β-THALASSEMIA: A CASE REPORT ON SUCCESSFUL TREATMENT OF CMV PNEUMONIA, DAH, AND BOS (EBMT 2026) - "She underwent a matched unrelated donor (9/10 HLA-matched) allo-HSCT following a myeloablative conditioning regimen (fludarabine, busulfan, cyclophosphamide, ATG). GVHD prophylaxis included tacrolimus, methotrexate, mycophenolate mofetil, and pre-emptive infusions of umbilical cord-derived mesenchymal stromal cells (UC-MSCs)...The early post-transplant course was complicated by steroid-refractory, grade III acute GVHD (skin and gut), which was successfully managed with a second-line regimen of ruxolitinib, CD25 monoclonal antibody, budesonide, and additional UC-MSCs...Initial anti-CMV therapy (acyclovir/foscarnet) failed, indicating a refractory infection...Treatment with the FAM regimen (fluticasone, azithromycin, montelukast) combined with further cycles of UC-MSCs resulted in significant clinical and radiological improvement by day +220... This complex case illustrates the cascade of severe complications—refractory aGVHD, life-threatening CMV pneumonia with DAH, and..."

Case report • Clinical • Acute Graft versus Host Disease • Beta-Thalassemia • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

CLINICAL CHARACTERISTICS AND TREATMENT RESPONSE OF NON-INFECTIOUS PULMONARY COMPLICATIONS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER RETROSPECTIVE ANALYSIS (EBMT 2026) - "Commonly used drugs included calcineurin inhibitors (tacrolimus/cyclosporine), corticosteroids, JAK inhibitors (e.g., ruxolitinib), and components of the "FAM" regimen (fluticasone, azithromycin, montelukast). NIPCs following HSCT are a significant complication affecting long-term quality of life. Their clinical presentation is often nonspecific and coexists with chronic GVHD in other organs. Exertional dyspnea is a core symptom, while obstructive patterns on PFTs and air trapping on CT are key diagnostic clues."

Retrospective data • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Cough • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Pulmonary Disease • Respiratory Diseases • Transplantation

Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) (clinicaltrials.gov) - P2 | N=80 | Recruiting | Sponsor: Cedars-Sinai Medical Center | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Apr 2025 ➔ Jun 2027

Trial completion date • Trial primary completion date • Chronic Rhinosinusitis With Nasal Polyps • Otorhinolaryngology

PaNaMa 12782: Inhaled corticosteroids in young children with episodic wheezing: a multicenter cluster RCT (clinicaltrialsregister.eu) - P4 | N=285 | Not yet recruiting | Sponsor: Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

New P4 trial

INCORPORATING ENVIRONMENTAL IMPACT INTO HEALTH TECHNOLOGY ASSESSMENT: A CASE STUDY IN INHALERS (ISPOR 2026) - "Recent evidence suggests that fluticasone-umeclidinium-vilanterol (Trelegy) and budesonide-glycopyrrolate-formoterol (Breztri ) have similar effectiveness and safety profiles. This illustrative analysis shows how HTA agencies can incorporate the climate impact of therapies into budget impact analysis using the social costs of GHG. These estimates provide additional context to the broader impact of treatments. Moreover, this broader calculation of costs could be potentially useful for price negotiations and formulary design."

Case study • Clinical • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

An Indirect Comparison of Budesonide/ Glycopyrrolate/ Formoterol Fumarate Versus Fluticasone/ Umeclidinium/ Vilanterol in Adults With Uncontrolled Asthma From a US Perspective: A Systematic Review and Network Meta Analysis (ATS 2026) - No abstract available

Retrospective data • Review • Asthma • Immunology • Respiratory Diseases

Fluticasone- vs Budesonide-Based Dual Therapy for COPD. (PubMed, JAMA Netw Open) - "In this cohort study of new ICS-LABA users with COPD, once-daily dry powder fluticasone furoate-vilanterol inhalers were associated with slightly improved clinical outcomes compared with twice-daily metered-dose budesonide-formoterol inhalers and twice-daily dry powder fluticasone propionate-salmeterol inhalers. Further studies are needed to explore potential intraclass differences among inhalers used to treat COPD."

Clinical • Journal • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Single vs Dual Lactose-Polyethylene Glycol 3000 Microcarrier Systems for Pulmonary Salmeterol and Fluticasone Targeted Delivery. (PubMed, Drug Des Devel Ther) - "Dual-microcarrier increased pulmonary drug retention with a marginal rise in systemic drug levels and reduced inflammatory lymphocytes/eosinophils/neutrophils infiltration, IL-4/5/9/13 release, mucus production, and bronchoconstriction. Dual-microcarrier is more efficient than single-microcarrier in pulmonary SX/FP delivery."

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • IL4

Management of CMV Pneumonia, DAH, and BOS Following HSCT in a Child with β-Thalassemia: A Case Report. (PubMed, J Inflamm Res) - "The patient received repeated infusions of umbilical cord-derived mesenchymal stromal cells (UC-MSCs), initially for refractory intestinal aGVHD and later in conjunction with the FAM regimen (fluticasone, azithromycin, montelukast) for BOS, ultimately achieving full clinical recovery. This case highlights two key management insights: (1) the ganciclovir-letermovir combination can be effective in pediatric refractory CMV pneumonia, and (2) sequential UC-MSC administration may contribute to controlling both acute GVHD and late pulmonary complications. Finally, multidisciplinary collaboration and individualized strategies are essential in managing such complex post-transplant pulmonary syndromes in children."

Journal • Acute Graft versus Host Disease • Beta-Thalassemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Pediatrics • Pneumonia • Pulmonary Disease • Respiratory Diseases • Transplantation

Pharmacoeconomic Evaluation of Allergic Rhinitis in a Northeastern Mexican Population (AAAAI 2026) - "Cetirizine and intranasal fluticasone were the most used medications. Conclusions Allergic rhinitis represents a significant financial burden in Mexico, with nearly one-third of the minimum wage required monthly for adequate management. The awareness of costs could help increase treatment adherence, identify better treatment options, and develop conscientious healthcare policies."

Clinical • HEOR • Late-breaking abstract • Allergic Rhinitis • Immunology • Inflammation

Effects Of Flovent Discontinuation On Pediatric Asthmatic Healthcare Utilization And Prescription Practices (AAAAI 2026) - "Rationale On January 1, 2024, manufacturer GlaxoSmithKline discontinued brand name fluticasone hydrofluoroalkane (Flovent), a commonly prescribed inhaled corticosteroid (ICS) for asthma control...In the year following Flovent discontinuation, age-inappropriate asthma controller prescriptions increased in former Flovent patients 6-fold compared to a 3-fold increase in asthma patients not prescribed Flovent (p=0.002). Conclusions Following Flovent discontinuation, affected patients were more likely to receive inappropriate therapeutic interchanges and had more asthma hospitalizations."

Clinical • HEOR • Asthma • Immunology • Pediatrics • Respiratory Diseases

Oscillometry Helps Diagnose Pre-COPD and Fluticasone/ Vilanterol Could Help Treat It: Results From Indian Early COPD Network Pilot Study (ATS 2026) - No abstract available

Clinical • Late-breaking abstract • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Azelastine-fluticasone intranasal therapy: A paradigm shift in pediatric allergic rhinitis management. A point of view of the Italian Society of Pediatric Allergy and Immunology. (PubMed, Pediatr Allergy Immunol) - "Azelastine-fluticasone combination intranasal therapy represents a significant paradigm shift in pediatric allergic rhinitis management. It offers superior efficacy, an excellent safety profile, and practical advantages that foster better treatment adherence. This therapeutic approach is well-aligned with contemporary guidelines and is increasingly being adopted in clinical practice for the management of moderate to severe AR in children and adolescents."

Journal • Allergic Rhinitis • Allergy • Immunology • Inflammation • Pediatrics

Case 347. (PubMed, Radiology) - "She had a documented history of asthma and had been using the inhaled steroid fluticasone (100 µg/d) since at least 2013, along with an albuterol inhaler as needed for the past 3 years...Laryngoscopy revealed normal bilateral vocal cord movement but pachydermatous changes in the mucosa outlining the interarytenoid fold, which can be associated with nasopharyngeal reflux or chronic infection. As a part of the diagnostic workup for the increased shortness of breath, CT screening studies acquired in the patient in 2019 (Fig 1A), 2023 (Fig 1B), and 2024 (Fig 2) were reviewed."

Journal • Allergic Rhinitis • Asthma • Cough • Dysphonia • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hematological Disorders • Immunology • Infectious Disease • Lung Cancer • Oncology • Otorhinolaryngology • Pain • Pulmonary Disease • Respiratory Diseases • Rheumatology • Solid Tumor

Combined azelastine fluticasone nasal spray versus fluticasone propionate nasal spray in postoperative management of central compartment atopic disease (CCAD). (PubMed, Front Pharmacol) - "Combined steroid/H1 blocker sprays provided better postoperative control of CCAD than steroid sprays. The synergistic action of H1 blockers in the combined sprays confirms the association between CCAD and nasal allergy and encourages us to consider it as a first line treatment for the disease."

Clinical • Journal • Allergy • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Cost Utility Analysis of Fluticasone Exhalation Delivery System Versus Budesonide Nasal Irrigation for Chronic Rhinosinusitis With Nasal Polyps. (PubMed, Int Forum Allergy Rhinol) - "Compared to EDS-FLU, SNI is the cost-effective strategy for treating CRSwNP following FESS. Changes in drug pricing and improvements in patient selection may cause adjustments in the most cost-effective strategy for CRSwNP management."

HEOR • Journal • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION (clinicaltrials.gov) - P4 | N=61 | Active, not recruiting | Sponsor: Pamukkale University

New P4 trial • Allergic Rhinitis • Immunology • Inflammation

CONSIDERATION OF PULMONARY EMBOLISM IN WORSENING DYSPNEA AMONG PATIENTS WITH CONGESTIVE HEART FAILURE (WRMC 2026) - "Her medications included Aspirin, Carvedilol, Lasix, Spironolactone, Valsartan, a fluticasone-umeclidinium-vilanterol inhaler, and an albuterol nebulizer. In this patient, despite a history of CHF and elevated BNP, the absence of pulmonary congestion on CXR and significant fluid overload warranted further evaluation, ultimately resulting in the diagnosis of PE. Maintaining a broad differential is critical in patients presenting with dyspnea to prevent misdiagnosis and ensure timely recognition of pulmonary embolism."

Clinical • Cardiovascular • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Heart Failure • Immunology • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases

Drug-associated tongue discoloration: a comprehensive assessment of USFDA adverse event reporting system using disproportionality analysis. (PubMed, BDJ Open) - "This comprehensive signal detection revealed several high-priority drug-tongue condition associations using large-scale pharmacovigilance data. Findings carry implications for guiding clinical practice through enhancing adverse effect monitoring for high-risk medications. Priority signals merit validation through further research to optimize benefit-risk assessment and reduce preventable tongue disorders."

Adverse events • Journal

Exploration Novel Therapeutic Targets for Periodontitis via Stress Granules Biomarkers. (PubMed, Int Dent J) - "This study identified four SGs-related biomarkers in PD and proposed potential therapeutic targets, providing preliminary insights into its pathogenesis that warrant further experimental validation at the protein and functional levels."

Biomarker • Journal • Cardiovascular • Dental Disorders • Diabetes • Metabolic Disorders • Periodontitis • CD31 • CEBPB • EGFR • ELF1 • IL18 • PECAM1 • STAT3

Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA) (clinicaltrials.gov) - P3 | N=174 | Not yet recruiting | Sponsor: Eurofarma Laboratorios S.A.

Head-to-Head • New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases